Prospective Registry of ihtDEStiny® Coronary Stent in Regular PCI Practice

Prior treatment

• Other DES implantation during index PCI, or 30 days before of after index PCI
• PCI at surgical grafts

Other illness

• Killip class 3-4 Acute Coronary Syndromes (ACS)
• High bleeding risk with dual antiplatelet intolerance for at least 3 months (or 6 months for ACS PCI)
• Allergy or hypersensitivity to sirolimus
• Patients requiring surgery (cardiac or non-cardiac) in the next 3 months after index PCI

Age

• Patients with life expectancy \<2 years

Other

• Patient refusal to participate in the study
• Pregnancy
• PCI for in-stent restenosis
• Patients included in other trials or clinical studies

• ≥18 years old
• PCI and stent implantation indication according to ESC Myocardial Revascularization Guidelines
• 1 or more stenosis at native coronary anatomy, in a 2-4mm vessel size, where 1 or more ihtDEStiny® drug eluting stent were implanted (or attempted to be implanted).
• Informed consent signed after PCI